Hypertrophic cardiomyopathy
Conditions
Interventions
Experimental group:Metoprolol Succinate Sustained-release Tablets combined with candesartan treatment
Control group:Metoprolol Succinate Sustained-release Tablets monotherapy
Sponsors
The First Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 to 65 years old will be eligible for inclusion if they had unexplained left ventricular hypertrophy with either a maximum wall thickness of 15 mm or more on echocardiography or borderline hypertrophy (maximum wall thickness 13-14 mm) on echocardiography and at least one first-degree relative with hypertrophic cardiomyopathy. Only patients with the left ventricular ejection fraction more than 50% will be eligible.
Exclusion criteria
Exclusion criteria: Known hypersensitivity to losartan or metoprolol, current treatment with an ACE inhibitor or ARB, symptomatic hypotension and/or resting systolic blood pressure lower than 100 mmHg, symptomatic bradycardia and/or resting heart rate lower than 60 betas per min, or second or third degree heart block without a pacemaker, patients with asthma or chronic obstructive pulmonary disease that are expected to be intolerant to large doses of metoprolol succinate, known or suspected unilateral or bilateral renal artery stenosis, renal insufficiency with an estimated glomerular filtration rate of less than 30 mL/min per 1.73m^2, hyperkalemia, atrial fibrillation that affect image quality of cardiac magnetic resonance history of stoke or myocardial infarction within the past 3 months, recent (within 6 months) septal reduction therapy, present or planned pregnancy, and expected non-compliance with research protocol or treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in left ventricular mass from baseline to 24 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| the change in the maximum thickness of left ventricular wall from baseline;the change in the maximum volume of the left atrium from baseline;the rehospitalization rate;cardiovascular adverse events including sudden cardiac death, malignant arrhythmia (ventricular tachycardia or ventricular fibrillation), heart failure and acute coronary syndrome;the change in the activity tolerance from baseline;the change in the cardiac diastolic function from baseline; | — |
Countries
China
Contacts
Public ContactYugang Dong
The First Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed